Corvus Pharmaceuticals (CRVS) Other Non-Current Assets (2016 - 2026)

Corvus Pharmaceuticals' Other Non-Current Assets history runs 11 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 173.45% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 173.45% YoY), while the FY2025 annual figure was $855000.0, up 35.28% from the prior year.
• Other Non-Current Assets was $1.7 million for Q1 2026 at Corvus Pharmaceuticals, up from $855000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $1.7 million in Q1 2026 to a low of $89000.0 in Q3 2023.
• Historically, Other Non-Current Assets has averaged $415823.5 across 5 years, with a median of $236000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets plunged 78.11% in 2022, then soared 610.11% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $129000.0 in 2022, then plunged by 31.01% to $89000.0 in 2023, then jumped by 610.11% to $632000.0 in 2024, then surged by 35.28% to $855000.0 in 2025, then surged by 101.17% to $1.7 million in 2026.
• The last three Other Non-Current Assets figures came in at $1.7 million (Q1 2026), $855000.0 (Q4 2025), and $852000.0 (Q3 2025), per Business Quant data.